Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board
April 16, 2025
Biotechnology
-
-
PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Custom IT Packaging Company
April 16, 2025
-
INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom(TM) Manufacturing for Commercial Readiness
April 14, 2025
-
Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships
April 14, 2025
-
OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans
April 10, 2025
-
Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.
April 8, 2025
-
Renovaro Provides Update to Definitive Agreement with Predictive Oncology
April 4, 2025
-
Nutriband Signs Partnership Agreement with Charlotte FC
April 4, 2025
-
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics
March 31, 2025
-
Dominari Holdings Investment, American Data Centers, Becomes American Bitcoin in Transformative Bitcoin Mining Deal with Hut 8
March 31, 2025
-
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
March 28, 2025
-
Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection
March 28, 2025
-
Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk
March 24, 2025
-
PharmAla Contracts with Partner to Act as US Distributor
March 24, 2025
-
Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases
March 24, 2025
-
Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million
March 21, 2025